ストックスクリーナーアプリを入手
2.02
6.48%
-0.14
プレマーケット:
2.05
0.03
+1.49%
前日終値:
$2.16
開ける：
$2.16
24時間の取引高:
268.44K
Relative Volume:
0.94
時価総額：
$54.69M
収益：
-
当期純損益:
$-49.81M
株価収益率:
-0.9369
EPS:
-2.156
ネットキャッシュフロー:
$-42.93M
1週間 パフォーマンス:
-20.16%
1か月 パフォーマンス:
-27.86%
6か月 パフォーマンス:
-81.92%
1年 パフォーマンス:
-86.13%
1日の値動き範囲:
$2.00
$2.19
1週間の範囲:
$2.00
$2.55
52週間の値動き範囲:
$2.00
$17.55
Alto Neuroscience Inc Stock (ANRO) Company Profile
名前
Alto Neuroscience Inc
セクター
電話
773-255-5012
住所
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
ANRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
2.02 | 54.69M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-23 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-09-03 | 開始されました | Wedbush | Outperform |
| 2024-02-27 | 開始されました | Jefferies | Buy |
| 2024-02-27 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-27 | 開始されました | Stifel | Buy |
| 2024-02-27 | 開始されました | TD Cowen | Outperform |
| 2024-02-27 | 開始されました | William Blair | Outperform |
すべてを表示
Alto Neuroscience Inc (ANRO) 最新ニュース
Charles Schwab Investment Management Inc. Sells 32,137 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Bank of New York Mellon Corp - Defense World
ANRO stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
What is William Blair’s Forecast for ANRO Q1 Earnings? - Defense World
What is Wedbush’s Estimate for ANRO FY2029 Earnings? - Defense World
Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75 - Defense World
William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience says its funded through 2028 - Green Market Report
ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings - Nasdaq
Alto Neuroscience Inc. (ANRO) reports earnings - Quartz
Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights - Marketscreener.com
Alto Neuroscience, Inc. SEC 10-K Report - TradingView
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Thursday - Defense World
ANRO stock touches 52-week low at $3.23 amid market challenges - MSN
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Rhumbline Advisers - Defense World
Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR
Alto Neuroscience (NYSE:ANRO) Trading Up 8.8% – Should You Buy? - Defense World
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock - Asianet Newsable
1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March - MSN
1 ‘Strong Buy’ Penny Stock With 270% Upside To Load Up On In March - Barchart
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Alto Neuroscience advances trial for depression treatment - MSN
ANRO stock touches 52-week low at $2.97 amid market challenges - Investing.com Canada
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker - Marketscreener.com
Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care - StockTitan
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Business Wire
Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Stifel maintains Buy on Alto Neuroscience stock, $10 target - MSN
Alto Neuroscience advances trial for depression treatment By Investing.com - Investing.com Australia
Stifel maintains Buy on Alto Neuroscience stock, $10 target By Investing.com - Investing.com Nigeria
Alto Neuroscience : Corporate Presentation -February 12, 2025 at 08:29 am EST - Marketscreener.com
Alto Neuroscience announces interim analysis from ALTO-300 trial - TipRanks
Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial - Marketscreener.com
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - The Bakersfield Californian
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation - Louisiana First News
Schizophrenia Drugs Market reached US$ 10.03 billion in 2024 - openPR
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average Price Target from Analysts - MarketBeat
Alto Neuroscience announces $75 million ATM offering - MSN
Alto Neuroscience Files For Mixed Shelf Of Up To $300 Million -February 03, 2025 at 05:06 pm EST - Marketscreener.com
Alto Neuroscience announces $75 million ATM offering By Investing.com - Investing.com UK
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Precision neuropsychiatry spotlight: a BioCentury podcast - BioCentury
JPMorgan Chase & Co. Acquires 20,536 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience Inc (ANRO) 財務データ
収益
当期純利益
現金流量
EPS
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):